Seeing Is Believing
Currently out of the existing stock ratings of Andrew Peters, 33 are a BUY (97.06%), 1 are a HOLD (2.94%).
Analyst Andrew Peters works with a stock forecast success ratio of 86.75% fulfilled within 659.56 days on average. Previously, Andrew Peters worked at DEUTSCHE BANK, UBS.
Andrew Peters’s has documented 79 price targets and ratings displayed on 9 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ESPR, Esperion Therapeutics at 03-May-2018.
Analyst best performing recommendations are on EXEL (EXELIXIS).
The best stock recommendation documented was for HALO (HALOZYME THERAPEUTICS) at 11/3/2016. The price target of $12 was fulfilled within 7 days with a profit of $3.54 (41.84%) receiving and performance score of 59.78.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
89
$6.9 (8.40%)
91
11 days ago
2/7 (28.57%)
$8.09 (10.00%)
33
Buy
112
$29.9 (36.42%)
117
11 days ago
13/18 (72.22%)
$31.09 (38.43%)
250
Hold
85
$2.9 (3.53%)
83
12 days ago
3/4 (75%)
$2.83 (3.44%)
81
Buy
110
$27.9 (33.98%)
86
12 days ago
4/6 (66.67%)
$27.83 (33.87%)
179
Hold
100
$17.9 (21.80%)
100
2 months 14 days ago
1/6 (16.67%)
$8.76 (9.60%)
41
What Year was the first public recommendation made by Andrew Peters?